Arvig Answering Solutions Earns 2025 CAM-X Award for 20th Year
Verizon Expands Home Internet to More Customers with New Lite Plan
CodeEye Launches IRIS 3.0: Canada’s Sovereign, Unified Application Security, Built to Eliminate Blind Spots
Mimecast Unveils AI-Driven Human Risk Platform Innovations at Elevate 2025Â
New Benevity Impact Labs Research Reveals a Confidence Gap Among Global Grantmakers
BOSTON and LONDON, Sept. 21, 2023 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX) (“Akari”…
SAN MATEO, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) — Bluejay Therapeutics, Inc. a private clinical…
SAN MATEO, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) — Bluejay Therapeutics, Inc. a private clinical…
Successful Audit of the Company’s State-of-the-Art Manufacturing Facility Represents a Key Milestone Toward Plan to…
Successful Audit of the Company’s State-of-the-Art Manufacturing Facility Represents a Key Milestone Toward Plan to…
MALVERN, Pa., Sept. 21, 2023 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ:…
– Phase 2a NASH protocol on track to be submitted to the IND in Q4…
MALVERN, Pa., Sept. 21, 2023 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ:…
– Phase 2a NASH protocol on track to be submitted to the IND in Q4…
– New data from multi-dose GLP toxicology study of SNS-101 in cynomolgus monkeys further support…
– New data from multi-dose GLP toxicology study of SNS-101 in cynomolgus monkeys further support…
FILSPARI® (sparsentan) achieved a clinically meaningful difference vs. irbesartan in eGFR total slope (1.0 mL/min/1.73m2…
FILSPARI® (sparsentan) achieved a clinically meaningful difference vs. irbesartan in eGFR total slope (1.0 mL/min/1.73m2…
LONDON, Sept. 21, 2023 (GLOBE NEWSWIRE) — Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or…
LONDON, Sept. 21, 2023 (GLOBE NEWSWIRE) — Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or…
mTNX-1700 (mTFF2-MSA) suppresses tumor growth and increases survival rates in preclinical colorectal cancer models mTNX-1700…
– Initiation of Phase 1 clinical trial marks Entrada’s transition into a clinical company –…
mTNX-1700 (mTFF2-MSA) suppresses tumor growth and increases survival rates in preclinical colorectal cancer models mTNX-1700…
NEW YORK and LEAMINGTON, Ontario, Sept. 21, 2023 (GLOBE NEWSWIRE) — Tilray Brands, Inc. (“Tilray”…
– Initiation of Phase 1 clinical trial marks Entrada’s transition into a clinical company –…